This is a press release by OctoPlus N.V. ("OctoPlus"or the "Company") pursuant to the provisions of Article 5:25i of the Dutch Act on the Financial Supervision (Wet op het financieel toezicht) and Article 4, paragraph 3 of the Dutch Public Takeover Decree (Besluit openbare biedingen Wft), in connection with the recommended public offer (the "Offer") by Reddy Netherlands B.V. (the "Offeror"), a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's") for all the issued and outstanding ordinary shares (the "Shares") in the capital of OctoPlus. SHAREHOLDERS OCTOPLUS APPOINT TWO NEW SUPERVISORY BOARD MEMBERS OctoPlus N.V. ("OctoPlus")(Euronext: OCTO), announces today that its Extraordinary General Meeting of Shareholders has appointed Mr. Prasad and Mr. Ananthanarayanan to the Supervisory Board. The appointment is subject to the condition precedent that the Offer is declared unconditional and is settled. The new members of the Supervisory Board have been appointed for a period of four years and join current member Staf Van Reet to form a Supervisory Board of three members. Mr. Prasad has been appointed as chairman of the Supervisory Board. The shareholders also approved the other agenda item of today's meeting. Minutes of the meeting will be available within three months on OctoPlus' website For further information, please contact: Investor relations: telephone number +31 (71) 524 1071, or send an e-mail to Investor Relations at About OctoPlus OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult to formulate active pharmaceutical ingredients. OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO. For more information about OctoPlus, please visit our website In addition, OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics. This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus and the industry in which it operates. These statements are based on OctoPlus' current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version. Click here for the press release in PDF: This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: OctoPlus N.V. via Thomson Reuters ONE [HUG#1670571]